Cambridge Centre for AI in Medicine: against COVID-19 Hub
COGENT (COvid-19 Genomic Evaluation of Novel Therapies)
Research Group: Cardiovascular Epidemiology Unit
Project Description: The COGENT (COvid-19 Genomic Evaluation of Novel Therapies) portfolio of studies is an international collaboration of investigators lead by the Centre for Naturally Randomized Trials at Cambridge that aims to conduct an integrated suite of studies that a) nests a series of naturally randomized genetic experiments within an ensemble of artificial intelligence algorithms to identify each person’s unique genomic vulnerability to developing severe symptoms if infected with SARS-CoV-2; b) discover what causes some people to be more vulnerable to developing severe symptoms when they become infected with SARS-C0V-2; c) identify targets for therapies that can decrease the risk of developing severe symptoms if infected with SARS-CoV-2; d) conduct a portfolio of pragmatic naturally randomized trials to identify therapies that can potentially most effectively prevent the development of severe symptoms of SARS-C0V-2 infection; and e) use this information to rapidly design and conduct a series of adaptive pragmatic clinical trials to evaluate the clinical safety and efficacy of the identified novel therapies to prevent progression to severe complications among persons infected with SARS-CoV-2.
https://www.phpc.cam.ac.uk/covid-19-research-projects/
Collaborators: Cambridge Centre for Naturally Randomized Trials (lead); Cambridge Centre for AI in Medicine; TIMI Study Group Harvard Medical School; Imperial College London Clinical Trial Unit; Monash Heart; Oxford CTSU; University of Milan Department of Pharmacological and Biomolecular Sciences, University of Bristol; 23and Me; Benevolent AI
Research Group: Cardiovascular Epidemiology Unit
Project Description: The COGENT (COvid-19 Genomic Evaluation of Novel Therapies) portfolio of studies is an international collaboration of investigators lead by the Centre for Naturally Randomized Trials at Cambridge that aims to conduct an integrated suite of studies that a) nests a series of naturally randomized genetic experiments within an ensemble of artificial intelligence algorithms to identify each person’s unique genomic vulnerability to developing severe symptoms if infected with SARS-CoV-2; b) discover what causes some people to be more vulnerable to developing severe symptoms when they become infected with SARS-C0V-2; c) identify targets for therapies that can decrease the risk of developing severe symptoms if infected with SARS-CoV-2; d) conduct a portfolio of pragmatic naturally randomized trials to identify therapies that can potentially most effectively prevent the development of severe symptoms of SARS-C0V-2 infection; and e) use this information to rapidly design and conduct a series of adaptive pragmatic clinical trials to evaluate the clinical safety and efficacy of the identified novel therapies to prevent progression to severe complications among persons infected with SARS-CoV-2.
https://www.phpc.cam.ac.uk/covid-19-research-projects/
Collaborators: Cambridge Centre for Naturally Randomized Trials (lead); Cambridge Centre for AI in Medicine; TIMI Study Group Harvard Medical School; Imperial College London Clinical Trial Unit; Monash Heart; Oxford CTSU; University of Milan Department of Pharmacological and Biomolecular Sciences, University of Bristol; 23and Me; Benevolent AI
Connections
Connections from
Technology:
COVID Labs/Universities
Industry:
COVID R&D
Headquarters:
United Kingdom
Founded Date:
N/A
Employees Number:
N/A
Funding Status:
N/A
Register and Claim Ownership